According to Zhitong Finance App News, Nanjing Pharmaceutical (600713.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved operating income of 27.823 billion yuan, a year-on-year decrease of 0.52%; net profit attributable to shareholders of listed companies was 294 million yuan, up 1.10% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 283 million yuan, up 8.12% year on year; basic earnings per share was 0.229 yuan; the company plans to distribute a cash dividend of 0.9 yuan (tax included) for every 10 shares.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.